Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study.
Khanna D, Tseng CH, Furst DE, Clements PJ, Elashoff R, Roth M, Elashoff D, Tashkin DP; for Scleroderma Lung Study Investigators. Khanna D, et al. Among authors: elashoff r, elashoff d. Rheumatology (Oxford). 2009 Dec;48(12):1537-40. doi: 10.1093/rheumatology/kep284. Epub 2009 Sep 23. Rheumatology (Oxford). 2009. PMID: 19776222 Free PMC article. Clinical Trial.
Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.
Tashkin DP, Volkmann ER, Tseng CH, Kim HJ, Goldin J, Clements P, Furst D, Khanna D, Kleerup E, Roth MD, Elashoff R. Tashkin DP, et al. Among authors: elashoff r. Ann Rheum Dis. 2016 Feb;75(2):374-81. doi: 10.1136/annrheumdis-2014-206076. Epub 2014 Dec 1. Ann Rheum Dis. 2016. PMID: 25452309 Clinical Trial.
Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study.
Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D, Roth MD, Clements P, Furst DE, Khanna D, Vasunilashorn S, Li G, Tashkin DP. Goldin J, et al. Among authors: elashoff r. Chest. 2009 Nov;136(5):1333-1340. doi: 10.1378/chest.09-0108. Chest. 2009. PMID: 19892673 Free PMC article. Clinical Trial.
Adverse events during the Scleroderma Lung Study.
Furst DE, Tseng CH, Clements PJ, Strange C, Tashkin DP, Roth MD, Khanna D, Li N, Elashoff R, Schraufnagel DE; Scleroderma Lung Study. Furst DE, et al. Among authors: elashoff r. Am J Med. 2011 May;124(5):459-67. doi: 10.1016/j.amjmed.2010.12.009. Am J Med. 2011. PMID: 21531236 Clinical Trial.
Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group.
Khanna D, Tseng CH, Farmani N, Steen V, Furst DE, Clements PJ, Roth MD, Goldin J, Elashoff R, Seibold JR, Saggar R, Tashkin DP. Khanna D, et al. Among authors: elashoff r. Arthritis Rheum. 2011 Oct;63(10):3078-85. doi: 10.1002/art.30467. Arthritis Rheum. 2011. PMID: 21618205 Free PMC article. Clinical Trial.
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, Sterz MG, Chung J, FitzGerald JD, Seibold JR, Varga J, Theodore A, Wigley FM, Silver RM, Steen VD, Mayes MD, Connolly MK, Fessler BJ, Rothfield NF, Mubarak K, Molitor J, Tashkin DP; Scleroderma Lung Study Group. Khanna D, et al. Among authors: elashoff r. Arthritis Rheum. 2005 Feb;52(2):592-600. doi: 10.1002/art.20787. Arthritis Rheum. 2005. PMID: 15692967 Free article. Clinical Trial.
292 results